> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Panel to Discuss Opioid Postmarketing Requirement
- URL: https://www.fdaweb.com/panel-to-discuss-opioid-postmarketing-requirement/
- Published: 2023-01-20T12:00:00.000Z
- Updated: 2026-09-14T18:12:31.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5153589

FDA has [announced ](https://www.fda.gov/advisory-committees/advisory-committee-calendar/april-19-2023-meeting-anesthetic-and-analgesic-drug-products-advisory-committee-meeting-announcement?ref=fdaweb.com)a 4/19 Anesthetic and Analgesic Drug Products Advisory Committee meeting to discuss a postmarketing requirement (PMR) issued to NDA application holders for extended-release and long-acting opioid analgesics. The PMR is intended to evaluate the products’ long-term efficacy and the risk of opioid-induced hyperalgesia. Additionally, panel members will discuss a clinical trial design that will address the objectives. FDA says an upcoming *Federal Register* notice will provide more detail and establish a docket for public comments.